Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Rachel J. Cook, Tamara Moyo, Jane L. Liesveld, David A. Rizzieri, Eytan M. Stein, Stephane De Botton, Gail J. Roboz, Mikkael A. Sekeres, Joseph G. Jurcic, Azra Raza, Robert L. Redner, Dale L. Bixby, Jorge E. Cortes, Kristin Stephens, Angela Volkert, Qing Kang, Emmanuelle Di Tomaso, David A. Roth, Carlos E Vigil
Institutions: OHSU Knight Cancer Institute, Vanderbilt University, University of Rochester Medicine, University of Rochester, Duke Medical Center, Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Fondation Gustave Roussy, Cornell University, Weill Cornell Medicine, Cleveland Clinic, Columbia University Irving Medical Center, UPMC Hillman Cancer Center, University of Michigan, The University of Texas MD Anderson Cancer Center, Syros Pharmaceuticals (United States), University of Iowa
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2908534057